Zafgen Inc., of Cambridge, Mass., which filed in April with the SEC, announced terms for its initial public offering (IPO), planning to raise $75 million from 5 million shares at a price range of $14 to $16. The company is targeting the obesity market with beloranib, a first-in-class selective methionine aminopeptidase 2 (MetAP2) inhibitor.